These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8024843)

  • 1. Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment.
    Oliveri MB; Mautalen C; Mega M; Rossi E
    Bone; 1994; 15(1):101-4. PubMed ID: 8024843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The osteodystrophy of congenital erythropoietic porphyria.
    Pullon HW; Bellingham AJ; Humphreys S; Cundy TF
    Bone; 1991; 12(2):89-92. PubMed ID: 2064845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate and osteoporosis prevention in liver transplant recipients.
    Pennisi P; Trombetti A; Giostra E; Mentha G; Rizzoli R; Fiore CE
    Rheumatol Int; 2007 Jan; 27(3):251-6. PubMed ID: 16944154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate.
    Kananen K; Volin L; Laitinen K; Alfthan H; Ruutu T; Välimäki MJ
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3877-85. PubMed ID: 15797959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
    Orr-Walker B; Wattie DJ; Evans MC; Reid IR
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Chapurlat RD; Delmas PD; Liens D; Meunier PJ
    J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital erythropoietic porphyria: a case report.
    Chiewchanvit S; Mahanupab P; Vanittanakom P
    J Med Assoc Thai; 1998 Dec; 81(12):1023-7. PubMed ID: 9916395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
    Landman JO; Hamdy NA; Pauwels EK; Papapoulos SE
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3465-8. PubMed ID: 8530584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate therapy as prevention of bone loss following renal transplantation.
    Fan SL; Almond MK; Ball E; Evans K; Cunningham J
    Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.